Co-load of silybin and doxorubicin by MoS2 nanosheets for synergetic chemotherapy and photothermal therapy of lung cancer
10.16438/j.0513-4870.2022-1324
- VernacularTitle:共载水飞蓟素和多柔比星的二硫化钼纳米片用于肺癌的协同化疗和光热治疗的联合治疗
- Author:
Hong CHEN
;
Min GUO
;
Zhi-huai CHEN
;
Xin-qi WEI
;
You-rui YANG
;
Jian LIU
;
Wei XU
- Publication Type:Research Article
- Keywords:
molybdenum disulfide;
silybin;
sialic acid;
synergetic chemotherapy;
photothermal chemotherapy
- From:
Acta Pharmaceutica Sinica
2023;58(3):560-570
- CountryChina
- Language:Chinese
-
Abstract:
The active ingredient of traditional Chinese medicine, silybin (SBN), can inhibit the proliferation of cancer cells and enhance the anticancer effect of doxorubicin (DOX). However, due to non-targeting and short half-life of SBN and DOX, as well as different administration routes and pharmacokinetic processes, this combination drug cannot act on the tumor in the set order, seriously eliminating the synergistic effect between them and limiting the effect in vivo. Therefore, we intended to construct a nano-delivery system based on molybdenum disulfide (MoS2), modified by polyethylene glycol (PEG) and sialic acid (SA), and co-loaded with SBN and DOX. The system induced the release of combined drugs under the dual-stimulation of pH and near infra-red (NIR), increased the free concentration of intracellular drugs, so as to achieve the synergistic effect between them. The animal welfare and experimental procedures were in accordance with the regulations of the Animal Ethics Committee of Fujian University of Traditional Chinese Medicine. MoS2-PEG-SA-SBN/DOX circulated in vivo, and effectively accumulated at tumor sites through enhanced permeability and retention effect (EPR) and SA-mediated active targeting. Under near infrared light irradiation, MoS2-PEG-SA-SBN/DOX realized the combination of synergistic chemotherapy and photothermal therapy for tumor, thus achieving excellent anti-tumor effect in vivo. This study can provide a new idea and strategy for the clinical treatment of lung cancer. Taken together, MoS2-PEG-SA-SBN/DOX can offer a new idea and strategy for the clinical treatment of lung cancer.
